U.S. health regulators declined to
approve a nasal spray that would have been the first needle-free
emergency treatment for allergic reactions and asked for further
tests, a move that left its.
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for
Benzinga Elon Musk-Backed Brain Implant Firm Neuralink Starts Participant Enrollment In Brain Implant Human Trial For Paralysis Elon Musk's brain-computer interface company, Neuralink, has initiated recruiting its first test subjects for human trials aimed at assisting individuals with paralysis in controlling devices. Neuralink announced that it has obtained approval from an independent institutional review board and the initial hospital site, enabling the commencement of recruitment for its fi